Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors. Neurocrine Biosciences  is betting the lab that the next blockbuster is a “hunger-blocker.” The bioscience company agreed yesterday to buy Soleno Therapeutics for $2.9 billion. Per share, Neurocrine’s paying more than a 30% premium on Soleno’s Friday closing price and greater than 50% on its average price for the past month. The acquisition focuses on Vykat XR, the first drug approved to ...